Definium Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Definium Therapeutics, Inc. (DFTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.60% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-02-26
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2022-09-30 was 2.98%, a 297.33% increase year-over-year.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2022-06-30 was 2.78%, a 456.00% increase year-over-year.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2022-03-31 was 2.26%, a 564.71% increase year-over-year.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2021-09-30 was 0.75%.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.60%, a 2.22% increase from fiscal 2024.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.50%, a 15.38% increase from fiscal 2023.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 3.90%, a 7.14% decline from fiscal 2022.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.20%, a 425.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2025-12-31 | 4.60% 10-K · filed 2026-02-26 | |||
| 2024-12-31 | 4.50% 10-K · filed 2026-02-26 | |||
| 2023-12-31 | 3.90% 10-K · filed 2025-03-06 | |||
| 2022-12-31 | 4.20% 10-K · filed 2024-02-28 | |||
| 2022-09-30 | 2.98% 10-Q · filed 2022-11-10 | 2.98% 10-Q · filed 2022-11-10 | ||
| 2022-06-30 | 2.78% 10-Q · filed 2022-08-11 | 2.78% 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | 2.26% 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | 0.80% 10-K · filed 2023-03-09 | |||
| 2021-09-30 | 0.75% 10-Q · filed 2022-11-10 | 0.75% 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | 0.50% 10-Q · filed 2022-08-11 | 0.50% 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | 0.34% 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | 1.10% 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cronos Group Inc. (CRON) | $1.223B | ||
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B |